Dihydroartemisinin is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs, is recommended as the first-line anti-malarial drug with low toxicity. Dihydroartemisinin possesses promising anticancer activities and induce cancer cell death through apoptotic pathways.

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.

Pannexin - 1 Fragment (4515)